Small-Molecule Inhibitors of HIV-1 Protease Dimerization Derived from Cross-Linked Interfacial Peptides
Michael Shultz
Angewandte Chemie International Edition, 2000
View PDFchevron_right
Macromolecular Inhibitors of HIV-1 Protease CHARACTERIZATION OF DESIGNED HETERODIMERS
James Rozzelle
Journal of Biological Chemistry, 2000
View PDFchevron_right
Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation
Charles Craik
Proceedings of the National Academy of Sciences, 1996
View PDFchevron_right
An alternative strategy for inhibiting multidrug-resistant mutants of the dimeric HIV-1 protease by targeting the subunit interface
Michele Reboud-ravaux
Biochemical Society Transactions, 2007
View PDFchevron_right
Toward the First Nonpeptidic Molecular Tong Inhibitor of Wild-Type and Mutated HIV-1 Protease Dimerization
Michele Reboud-ravaux
ChemMedChem, 2010
View PDFchevron_right
Structure of the protease from simian immunodeficiency virus: Complex with an irreversible nonpeptide inhibitor
Charles Craik
Biochemistry, 1993
View PDFchevron_right
Potent New Antiviral Compound Shows Similar Inhibition and Structural Interactions with Drug Resistant Mutants and Wild Type HIV-1 Protease †
Yuan-fang Wang, Irene Weber
Journal of Medicinal Chemistry, 2007
View PDFchevron_right
Yeast Two-Hybrid Assay for Examining Human Immunodeficiency Virus Protease Heterodimer Formation with Dominant-Negative Inhibitors and Multidrug-Resistant Variants
Charles Craik
Analytical Biochemistry, 2000
View PDFchevron_right
Dimer Disruption and Monomer Sequestration by Alkyl Tripeptides Are Successful Strategies for Inhibiting Wild-Type and Multidrug-Resistant Mutated HIV-1 Proteases †
Regis Vanderesse
Biochemistry, 2009
View PDFchevron_right
Conformationally constrained HIV-1 protease inhibitors
Joseph Vacca
Bioorganic & Medicinal Chemistry Letters, 1994
View PDFchevron_right
Structural Basis of HIV-1 and HIV-2 Protease Inhibition by a Monoclonal Antibody
J. Lescar
Structure, 2001
View PDFchevron_right
Discovery and optimization of nonpeptide HIV-1 protease inhibitors
John Domagala
Bioorganic & Medicinal Chemistry, 1996
View PDFchevron_right
Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis
Miguel Fernandes
Chemical Biology & Drug Design, 2007
View PDFchevron_right
Characterization of a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, A-790742
Larry Klein
Antimicrobial Agents and Chemotherapy, 2008
View PDFchevron_right
INHIBITORS OF HIV-1 PROTEASE: A Major Success of Structure-Assisted Drug Design 1
Alexander Wlodawer
Annual Review of Biophysics and Biomolecular Structure, 1998
View PDFchevron_right
Human immunodeficiency virus protease inhibitors From drug design to clinical studies
Chiara Atzori
Advanced Drug Delivery Reviews, 1997
View PDFchevron_right
Dimerization inhibitors of HIV1 reverse transcriptase, protease and integrase: A single mode of inhibition for the three HIV enzymes
Ana Felix
Antiviral Research, 2006
View PDFchevron_right
Future appeal of comparative studies on putative binding sites of HIV-1 virus-encoded proteolytic enzyme inhibitor of different Food and Drug Administration-approved compounds
SAMI MELEBARI
HIV & AIDS Review
View PDFchevron_right
New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors
Celia Schiffer
Current Opinion in HIV and AIDS, 2008
View PDFchevron_right
Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication
Jean-alain Fehrentz
Research in Virology, 1992
View PDFchevron_right
Cyclic HIV protease inhibitors capable of displacing the active site structural water molecule
Bruce Aungst
Drug Discovery Today, 1997
View PDFchevron_right
Molecular Recognition of Macrocyclic Peptidomimetic Inhibitors by HIV1 Protease † , ‡
David Fairlie
Biochemistry, 1999
View PDFchevron_right
Small-Sized Human Immunodeficiency Virus Type1 Protease Inhibitors Containing Allophenylnorstatine to Explore the S 2 ′ Pocket
Hamdy Abdel-Rahman
Journal of Medicinal Chemistry, 2009
View PDFchevron_right
Structural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV protease
Bruce Torbett
Acta Crystallographica Section D Biological Crystallography, 2011
View PDFchevron_right
An Orally Bioavailable HIV1 Protease Inhibitor Containing an Imidazole-Derived Peptide Bond Replacement: Crystallographic and Pharmacokinetic Analysis
Sherin S. Abdel-Meguid
Biochemistry, 1994
View PDFchevron_right
Novel Protease Inhibitors (PIs) Containing Macrocyclic Components and 3(R),3a(S),6a(R)-bis-Tetrahydrofuranylurethane That Are Potent against Multi-PI-Resistant HIV-1 Variants In Vitro
Masayuki Amano
Antimicrobial Agents and Chemotherapy, 2010
View PDFchevron_right
1 Evaluating the Substrate-Envelope Hypothesis: Structural Analysis of Novel HIV-1 Protease Inhibitors Designed to be Robust against Drug Resistance
Visvaldas Kairys
2016
View PDFchevron_right
GRL-0519, a Novel Oxatricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor (PI), Potently Suppresses Replication of a Wide Spectrum of Multi-PI-Resistant HIV-1 Variants In Vitro
Masayuki Amano
Antimicrobial Agents and Chemotherapy, 2013
View PDFchevron_right
New HIV protease inhibitors for drug-resistant viruses
S. Rusconi
Therapy, 2006
View PDFchevron_right